Shah R, Sabanathan S, Richardson J, Mearns A J, Goulden C
Department of Thoracic Surgery, Bradford Royal Infirmary, Bradford, U.K.
J Cardiovasc Surg (Torino). 1996 Apr;37(2):169-72.
Pulmonary resection remains the most appropriate treatment for localised bronchogenic carcinoma, since prognosis and outcome are currently dependent on surgical resectability. A retrospective analysis of our experience with three hundred and thirteen stage I (n=250) and stage II (n=63) patients treated surgically form the basis of this report. The initial pulmonary resection was lobectomy in 173 patients, bilobectomy in 38, sleeve lobectomy in 12, pneumonectomy in 59, wedge excision or segmentectomy in 31. The overall operative mortality was 3.2%; 4.03% for lobectomy and 1.6% for pneumonectomy. Morbidity was observed in 21 (6.7%) patients. Four out of sixteen small cell carcinoma patients had postoperative adjuvant chemotherapy. Survival in patients with stage I tumours was 71% at 5 years and 61% at 10 years compared with 41% at 5 years and 35% at 10 years for patients with stage II disease. The five year survival after pneumonectomy was significantly (p<0.05) better for both stage I and stage II lung cancer than after lobectomy. Five year survival in stage I carcinoma was not influenced by histological type, while there was statistically significant difference (p<0.05) in survival between adenocarcinoma (0%) and squamous cell carcinoma (46%) in stage II disease. We conclude that an aggressive surgical approach can provide an excellent prognosis for recovery and long term cure in most patients with early stage lung cancer.
肺切除术仍然是局限性支气管肺癌最恰当的治疗方法,因为目前预后和转归取决于手术可切除性。本报告基于对313例接受手术治疗的Ⅰ期(n = 250)和Ⅱ期(n = 63)患者的经验进行回顾性分析。最初的肺切除术包括173例肺叶切除术、38例双肺叶切除术、12例袖状肺叶切除术、59例全肺切除术、31例楔形切除或肺段切除术。总体手术死亡率为3.2%;肺叶切除术为4.03%,全肺切除术为1.6%。21例(6.7%)患者出现并发症。16例小细胞癌患者中有4例接受了术后辅助化疗。Ⅰ期肿瘤患者5年生存率为71%,10年生存率为61%;相比之下,Ⅱ期疾病患者5年生存率为41%,10年生存率为35%。对于Ⅰ期和Ⅱ期肺癌患者,全肺切除术后的5年生存率均显著(p<0.05)优于肺叶切除术后。Ⅰ期癌的5年生存率不受组织学类型影响,而在Ⅱ期疾病中,腺癌(0%)和鳞状细胞癌(46%)的生存率存在统计学显著差异(p<0.05)。我们得出结论,积极的手术方法可为大多数早期肺癌患者提供良好的恢复预后和长期治愈效果。